KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Equivalents: 2010-2024

Historic Cash & Equivalents for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $69.3 million.

  • Supernus Pharmaceuticals' Cash & Equivalents rose 377.92% to $151.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 377.92%. This contributed to the annual value of $69.3 million for FY2024, which is 7.63% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Cash & Equivalents stood at $69.3 million for FY2024, which was down 7.63% from $75.1 million recorded in FY2023.
  • Supernus Pharmaceuticals' Cash & Equivalents' 5-year high stood at $288.6 million during FY2020, with a 5-year trough of $69.3 million in FY2024.
  • Its 3-year average for Cash & Equivalents is $79.2 million, with a median of $75.1 million in 2023.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Cash & Equivalents spiked by 59.13% in 2020 and then slumped by 54.23% in 2022.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Cash & Equivalents stood at $288.6 million in 2020, then dropped by 29.52% to $203.4 million in 2021, then crashed by 54.23% to $93.1 million in 2022, then declined by 19.40% to $75.1 million in 2023, then declined by 7.63% to $69.3 million in 2024.